Aviceda’s lead product candidate, AVD−104, is being developed for the treatment of geographic atrophy (GA)

Aviceda’s lead product candidate, AVD−104, is being developed for the treatment of geographic atrophy (GA) secondary to age related macular degeneration (AMD). GA is a progressive and irreversible condition leading to vision loss.AVD−104 targets immune checkpoints in the eye, aiming to modulate the immune response and reduce the progression of GA.  Aviceda is exploring therapies for various fibrotic and inflammatory diseases, including those affecting the liver, lungs, and kidneys. The company’s pipeline includes multiple product candidates targeting different aspects of the immune system to treat chronic inflammation and fibrosis.